Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.

62 , 75 , 76 In MERIT, which randomized patients from Japan, China, and Russia to monthly mepolizumab, the nasal obstruction improved significantly, while the polyp‐size endpoint narrowly missed significance, mirroring the pattern seen in East Asian population subgroups in ANCHOR. 29 , 74 In parallel to CRSwNP, the subgroup analyses for the SWIFT trials for asthma also suggested lower asthma exacerbation rates in East Asian participants, compared with non‐Asian participants despite identical dosing, underscoring the role of population mix. 77 Hence, no conclusion regarding drug superiority can be drawn from the current trials, due to differences across enrollment mixes.

also in 112 other papers